

Signal Detection Methods for COVID-19 Vaccine Safety Surveillance

Michael Dymock

TELETHON
KIDS
INSTITUTE
Discover. Prevent. Cure.

WESFARMERS
CENTRE OF
VACCINES
& INFECTIOUS
DISEASES

5th July 2021

Proudly supported by the
people of Western Australia
through Channel 7's Telethon



Acknowledgements

AusVaxSafety

Leadership:

Kristine Macartney
Nick Wood
Chris Blyth
Tom Snelling
Paul Effler
David Durrheim
Mike Gold
Alan Leeb
Heather Gidding
Allen Cheng

NCIRS:

Alexis Pillsbury
Catherine Glover
Helen Quinn
Lucy Deng
Nicola Carter
Laura Lopez

SmartVax:

Ian Peters
Karin Orlemann

Vaxtracker:


Dave Durrheim
Patrick Cashman
Stephen Clarke

TKI/Uni Sydney

Julie Marsh
Michael Dymock
Yue Wu
Tim Spelman

Australian Government Department of Health
State & Territories Departments of Health
Therapeutic Goods Administration

Surveillance data have been provided by Vaxtracker and SmartVax. Surveys were sent on Day 3 after the vaccination, and data presented here are from surveys received up to 7 March 2021. These data are updated weekly.





Background

- Why do we use vaccines?
 - Immune system creates antibodies to fight a specific disease
 - Effective way to prevent disease (up to 3 million lives saved per year)
 - Protective against at least 20 diseases
- Why do we monitor safety?
 - Vaccination is safe and side effects are usually minor and temporary
 - All licensed vaccines are tested using clinical trials & monitored over time
 - You are far more likely to be seriously injured by a vaccine-preventable disease than by a vaccine
 - **BUT** there are always risks





COVID-19 Vaccines

- COVID-19 pandemic – over 3.9 million deaths (and counting)
- Many vaccines developed – Pfizer/BioNTech & Oxford/AstraZeneca
- Public concerns?
 - Comparatively short time from design to approval
 - Do the vaccines work?
 - Are the vaccines safe?
- Research questions?
 - Are the efficacy/safety profiles the same for everyone? Age/Sex/Pregnant?
 - When should the second dose be given? Coadministration?





What do we aim to do?


- Detailed break down of adverse event rates across subgroups
- Identify how these **change over time**
- Signal detection for possible **changes in safety profiles**
- Frequent reporting to TGA and Health
- Respond quickly to possible public concerns





What are we doing?

- Automated surveillance system to monitor adverse events





The Survey

- How do you receive the survey?
- When is it completed?
- What does the survey look like?

Dose	
Was this your first or second dose of the COVID-19 vaccine? <small>* must provide value</small>	<input type="radio"/> First <input type="radio"/> Second <input type="radio"/> I don't know
Reaction to vaccine	
Did you have any reactions <i>in the 3 days following your most recent COVID-19 vaccination?</i> <small>* must provide value</small>	<input checked="" type="radio"/> Yes <input type="radio"/> No
Medical assistance	
Did any of the symptoms cause you to seek advice/care from a doctor/healthcare professional? <small>* must provide value</small>	<input type="radio"/> Yes <input type="radio"/> No
Please select all the reactions that you experienced <i>in the 3 days following</i> vaccination	
Local reaction (pain, redness, swelling, itching at or near the injection site) <small>* must provide value</small>	<input type="radio"/> Yes <input type="radio"/> No
Fever <small>* must provide value</small>	<input type="radio"/> Yes <input type="radio"/> No





What do we do with the data?

- Clean the data
- Tabulate summaries of the data
- Analyse the data using **signal detection methods**:
 - **CUSUM Control Chart**
 - **Bayesian Logistic Model for Estimation and Predictive Probabilities**
- Produce reports for TGA/Health Departments
- Some data publicly available on AusVaxSafety and TGA websites





Worked Example – Simulated Data


Consider data only for one vaccine x dose combination
(e.g. Pfizer Dose 1).





CUSUM Method

- CUSUM = **CU**mulative **SUM** Control Chart (change detection)
- **More** events → **Increased** signal
- **Less** events → **Decreased** signal
- Requires:
 - Initial condition
 - Control threshold
 - Expected probability
 - Maximum probability
- Signal > threshold → Signal Detected
- Operating characteristics explored using simulation





CUSUM Input

- Initial Condition:
 - $X_0 = \frac{3}{2}$
- Expected Probability:
 - $p_E = 0.6\%$
- Maximum Probability:
 - $p_M = 1.4\%$
- Control Threshold:
 - $C = 3$

Data:





Time	Participants		Medical Attendances	
	<55	55+	<55	55+
1	1074	138	10	2
2	406	12	1	2
3	1224	848	6	1
4	319	294	3	1
5	979	48	1	0
6	566	174	3	1





CUSUM Output

Age Group	No. of Records	CUSUM Status
<55	4,568	No Signal Detected
55+	1,514	Signal Detected





Bayesian Logistic Model

- Participant subgroups: x = age, s = sex, g = covariate group
- Covariates include **state**, indigenous status and **medical history**
- Model no. of medical attendances (y) given no. of records (n) as Binomial with parameter (p) in each subgroup
- Model log odds of (p) with intercept (a), smooth function (g) and linear terms (B)

$$y_{xsg} \sim \text{Binomial}(n_{xsg}, p_{xsg})$$

$$\text{logit}(p_{xsg}) = a + g_s(x) + \sum_{q=1}^Q z_{gq} \beta_q$$



Bayesian Logistic Model

- Define prior distributions on parameters:
 - Gaussian Process for smooth function over age by sex

$$a \sim N(-4, 2)$$

$$g_s(\cdot) \sim GP(0, K(\cdot|\alpha_s, \rho_s))$$

$$K(x, x'|\alpha_s, \rho_s) = \alpha_s^2 \exp\left(-\frac{(x - x')^2}{2\rho_s^2}\right)$$


$$\alpha_s \sim N(0, 1)$$

$$\rho_s \sim \text{Gamma}(5, 0.5)$$

$$\beta_q \sim N(0, 3)$$




Fit of Gaussian Processes





Estimation of Probabilities


- Estimate **probability** of medical attendance in various subgroups
- Posterior distribution of (p) “averaged” over nuisance parameters to get marginal distribution





Predictive Probabilities

- Posterior Predictive distribution to predict forward number of medical attendances given known demographics of population
- How many medical attendances would we expect to see this week?
- Compare distribution of predicted number of medical attendances to actual observed number of medical attendances





Problems Encountered

- What issues have we encountered so far?
 - Data entry errors in some jurisdictions
 - Delay in some jurisdictions collecting data
 - Data storage and processing limitations
- How have they been resolved?
 - Careful quality control of reports
 - Regular meetings to discuss solutions





What's next?

- Publish findings
 - First one million responses
- Wait and watch how the population evolves
 - Younger (healthier?) population groups
- More vaccines
 - Moderna? Novavax? Johnson & Johnson?





Acknowledgements

